Anti-epilepsy Drugs Market – Highlights

Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. Epilepsy is the fourth most common neurological disorder and affects people of all ages. The patients are reported to loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. Increasing prevalence of the epilepsy, rising per capita healthcare expenditure, and increasing RD for the therapeutic procedures of the disease drives the market growth during the forecast period, 2022-2030. According to the World Health Organization in 2017, approximately 50 million people across the globe have epilepsy, making it one of the most common neurological diseases globally. Moreover, it was estimated that nearly 80% of the people with epilepsy live in low- and middle-income countries. Additionally, approval of several late-stage pipeline molecules, advancements in drugs modification and favourable government initiative fuels the market growth. However, side effects related to the therapeutic drugs, increasing generic competition and patent expirations are some of the restrains that for the growth during the forecast period.

The global anti-epilepsy drugs market is growing with the sound pace. According to a recent study report published by the Market Research Future, the anti-epilepsy drugs market size is projected to reach a final market value worth USD 4.8 billion at a CAGR of 3.30% in the forecast period 2022-2030.

Global Anti-epilepsy Drugs Market - Regional Analysis

On the regional backgrounds the Americas leads the global market for anti-epilepsy drugs owing to a well-developed healthcare sector, increasing prevalence of epilepsy market size and presence of the developed technologies within the region. According to the Centres for Disease Control and Prevention, in 2015, 1.2% of the total U.S. population had active epilepsy. Moreover, it was estimated that the yearly total direct and indirect cost of epilepsy in the U.S. was about USD 15.5 billion. Europe is second in the market due to rising healthcare expenditures, huge patient population and growing healthcare RD expenses by the government. The Asia Pacific region is the fastest growing region due to the developing economies like India and China which are increasing their healthcare expenditures and have huge patient population. Moreover, favourable government policies within the region fuels the market growth. Middle East and Africa have the least market share, especially due to the presence of poor economies and stringent government policies within the African region.

Segmental Review

Anti-epilepsy drugs market can be considered for types of seizures and generation.

The types of seizures include generalized seizures as well as partial-onset seizures.

There is first, second and third generations available in the global market. Third generation anti-epilepsy drugs like Breviate, Vimpat, and others have penetrated the worldwide market considerably and have been proven to be quite effective in treating epilepsy.

Global Anti-Epilepsy Drugs Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global anti-epilepsy drugs market report appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Pfizer Inc. is one of the major players of the global anti-epilepsy drugs market and is headquartered in the U.S. In 2015, the company’s total revenue was about USD 48,851 million and it reached USD 52,824 million in 2016. Such a significant increase in the global sales, enabled the company to invest a huge percentage of their sales into the research and development. In 2016, the company spent 14.9% of its total revenue into the RD enabling it to improve its product portfolio and launch new product, strengthening its position in the market.

In October 2016, Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations. Celgene has done an agreement with Abbott to develop and commercialize the diagnostic tests.

Anti-epilepsy Drugs Market Players

Anti-epilepsy drugs market players are Pfizer, Inc., Johnson Johnson, UCB Pharma Ltd., Abbott, GlaxoSmithKline plc, Novartis AG, Sanofi, Shire Pharmaceuticals Limited and Cephalon Inc.,

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com